News

Sarepta previously announced on July 25, 2018, that the FDA placed the program on clinical hold due to the presence of trace amounts of DNA fragment in research-grade

Farxiga was assessed in a trial, dubbed DECLARE-TIMI 58, in more than 17,000 T2D adult patients having multiple CV risk factors or established CV condition. In the five-year

Symbiosis recently hosted a successful inspection by the FDA for the aseptic manufacture of viral vector products for commercial supply into the U.S market at its GMP manufacturing

The interim analysis of the phase III IMpower132 study has demonstrated that Tecentriq and chemotherapy reduced the risk of disease worsening or death (progression-free survival (PFS)) by 40%

The expanded indication for the once-daily single inhaler triple therapy would enable use by patients not adequately treated by a long-acting muscarinic receptor antagonist (LAMA) and long-acting β2-agonist

In July 2017 Ibex Dedicate, a modular, technology-agnostic biomanufacturing concept, was launched as the first Ibex Solutions offering. Ibex Dedicate offers an innovative facility concept with reduced CAPEX

ROP is a rare and potentially blinding resulted due to abnormal development of retinal blood vessels in premature babies. The company has presented data from a Rainbow phase

THRUCOOL offers dedicated cold chain services to safeguard the integrity of pharmaceutical and healthcare shipments during air transportation. These include priority uplift and handling, quick ramp transfers at

BARDA is part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response. OPTN003, nasal nalmefene, is a potent, long-acting opioid antagonist